Albert Lockhart


  • 3805 Citations
1977 …2021
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Albert Lockhart is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 16 Similar Profiles
Neoplasms Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Maximum Tolerated Dose Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Adenocarcinoma Medicine & Life Sciences
Safety Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1977 2021

Pancreatic Neoplasms
Research Personnel
Conflict of Interest
Clinical Trials
Pharmaceutical Preparations
Genetic Polymorphisms
Drug Therapy
Drug-Related Side Effects and Adverse Reactions
Translational Medical Research

Research Output 1998 2019

  • 3805 Citations
  • 85 Article
  • 19 Review article
  • 5 Comment/debate
  • 1 Letter

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors

Weekes, C., Lockhart, A. C., Lee, J. J., Sturm, I., Cleton, A., Huang, F. & Lenz, H. J., Jan 1 2019, In : International Journal of Cancer.

Research output: Contribution to journalArticle

Open Access
Maximum Tolerated Dose
2 Citations (Scopus)

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Nature, (2018), 554, 7691, (189-194), 10.1038/nature25475)

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J. & 27 others, Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J. & Solit, D. B., Feb 28 2019, In : Nature. 566, 7745, p. E11-E12

Research output: Contribution to journalComment/debate


Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

Faessel, H., Nemunaitis, J., Bauer, T. M., Lockhart, A. C., Faller, D. V., Sedarati, F., Zhou, X., Venkatakrishnan, K. & Harvey, R. D., Jan 1 2019, In : British Journal of Clinical Pharmacology.

Research output: Contribution to journalArticle

Open Access
Cytochrome P-450 CYP3A

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma

Massard, C., Soria, J. C., Krauss, J., Gordon, M., Lockhart, A., Rasmussen, E., Upreti, V. V., Patel, S., Ngarmchamnanrith, G. & Henary, H., Jan 1 2019, In : Cancer Chemotherapy And Pharmacology.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Refractory materials
Anti-Idiotypic Antibodies

Folate Receptor α-Targeted89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer

Heo, G. S., Detering, L., Luehmann, H. P., Primeau, T., Lee, Y. S., Laforest, R., Li, S., Stec, J., Lim, K. H., Lockhart, A. C. & Liu, Y., Sep 3 2019, In : Molecular Pharmaceutics. 16, 9, p. 3996-4006 11 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Folic Acid